Sumitomo Pharma Q1 FY2027: Revenue Up 19.9% but Core Profit Down 11%

Sumitomo Pharma’s Q1 FY2027 consolidated results showed revenue of ¥129.5 billion, up 19.9% year on year, powered by US oncology and urology drugs. However, core operating profit slipped 11.0% to ¥18.1 billion, as higher promotion and R&D costs wiped out the gross profit uplift from the top-line gain. Reported operating profit also declined, by 10.8% to ¥18.2 billion.

Pretax profit surged 53.3% to ¥18.3 billion, and net profit attributable to owners of the parent jumped 51.7% to ¥17.0 billion, largely because the prior year’s foreign exchange loss reversed into a substantial foreign exchange gain this quarter. While the headline figures show a bottom-line recovery, the underlying operating performance requires scrutiny.

Regional revenue was led by the US at ¥94.3 billion (up ¥24.4 billion), representing over 70% of the total. Japan contributed ¥22.2 billion (up ¥1.0 billion) on steady sales of long-acting antipsychotics. Other regions fell to ¥13.0 billion (down ¥3.9 billion), mainly due to the partial divestment of the Asia business.

The gross profit margin declined on a product-mix shift from the Asia divestiture. SG&A expenses rose on US promotional activities, and R&D expenses (core basis) ballooned 41.2% year on year, driven by accelerated cancer trials and CNS pipeline advancement.

From FY2027, Sumitomo Pharma switched to a single ‘Pharmaceuticals’ reporting segment, discontinuing the previous Japan, North America, and Asia breakouts to reflect global operations. However, supplementary regional sales disclosures still reveal where growth is coming from.

United States: Revenue soared to ¥94.3 billion (up ¥24.4 billion, 72.8% of total sales). The advanced prostate cancer drug ORGOVYX (relugolix) and the overactive bladder treatment GEMTESA (vibegron) were the main growth drivers, more than offsetting erosion from the loss of exclusivity on the epilepsy drug APTIOM.

Japan: Revenue edged up to ¥22.2 billion (up ¥1.0 billion, 17.1% of total). The in-house transfer of long-acting injectable antipsychotics ZEPRION/ZEPRION TRI and growth of the type 2 diabetes treatment TWMEG contributed, partially offsetting the end of in-house sales for EQUA and EQMET.

Other: Revenue fell to ¥13.0 billion (down ¥3.9 billion, 10.0% of total). Higher exports to Europe could not offset the impact of the prior year’s partial Asia stake sale.

The result is an even heavier revenue reliance on the US, increasing sensitivity to both foreign exchange swings and US policy risks.

Total assets increased ¥40.3 billion from the prior fiscal year-end to ¥844.9 billion. Non-current assets grew on goodwill translation gains from a weaker yen and an increase in equity-method investments (such as an additional investment in regenerative cell medicine firm RACTHERA). Cash and cash equivalents also rose substantially, lifting current assets.

Total liabilities decreased ¥75.8 billion to ¥436.3 billion, mainly due to debt repayments (including a ¥60.0 billion repayment of long-term borrowings) and a decline in other current liabilities, signaling an improving financial position.

Equity attributable to owners of the parent jumped ¥116.1 billion to ¥408.6 billion, largely thanks to a ¥97.1 billion equity issuance via a public offering in June 2026. As a result, the equity ratio climbed to 48.4% from 36.4%, shoring up credit ratings and investment capacity.

Cash flows: Operating cash flow was a negative ¥7.4 billion (wider than the prior year’s ¥0.18 billion outflow) on higher working capital and lower other liabilities. Investing cash flow was near neutral at a ¥49 million inflow, as asset sales offset capex. Financing cash flow was a strong ¥39.2 billion inflow, with the equity offering proceeds far exceeding long-term debt repayments.

The annual dividend forecast for FY2027 remains undecided (interim dividend ¥0, year-end undecided). Although a continued zero payout is likely, market attention is on the possibility of a dividend resumption now that the balance sheet has been strengthened.

Core R&D spending surged 41.2% year on year to ¥11.4 billion in Q1, as Sumitomo Pharma pushes forward a broad pipeline refresh. In oncology, the menin inhibitor enzomenib (DSP-5336) moved into a pivotal Phase 2 trial for NPM1-mutated acute myeloid leukemia and completed the enrollment needed for an interim analysis in KMT2A-rearranged acute leukemia. These milestones drove up development expenses.

Multiple clinical programs are also advancing in the CNS area. The rapid rise in R&D costs is a deliberate investment in medium- to long-term growth, even if it weighs on near-term profitability.

Several risks stand out for Sumitomo Pharma based on its quarterly filing and business environment:

• Foreign exchange risk: With over 70% of revenue coming from the US, a stronger yen would significantly dent results. The company’s full-year assumption of ¥155/USD could prove optimistic if the yen appreciates further.
• Patent cliffs and competitive pressure: Revenue from APTIOM is declining following its loss of exclusivity, and other drugs face potential generic or competitive threats.
• Pipeline dependency: The future value of the company hinges heavily on clinical trial outcomes, particularly for enzomenib in acute leukemias.
• Rising SG&A costs: US promotion expenses are growing, making it harder to convert revenue gains into profit.
• Shrinking Asia presence: The partial divestment of the Asia business reduces geographic diversification and exposure to emerging-market growth.

Sumitomo Pharma left its FY2027 full-year consolidated forecasts unchanged: revenue ¥540.0 billion (up 19.1% year on year), operating profit ¥90.0 billion (down 16.2%), and net profit ¥77.0 billion (down 27.9%).

For the first time, it also issued a first-half (April–September) forecast: revenue ¥251.0 billion (up 10.5% from the prior year’s first half), operating profit ¥30.0 billion (down 68.8%), and net profit ¥26.0 billion (down 73.7%). The steep profit declines reflect the absence of large one-off gains from the Asia stake sale and forex gains that inflated the prior first half.

First-quarter progress against the full-year plan is 24.0% for revenue, 20.2% for operating profit, and 22.1% for net profit, suggesting a back-loaded pattern. The currency assumption of ¥155/USD, which is stronger than spot rates at the time of reporting, will be a key factor in meeting full-year targets.